A Phase 1, Randomized, [ADDRESS_839198] of ALXN1840 on the 
Metabolism of a CYP2CP Substrate in Healthy Participants  
Unique Protocol ID:  
NCT Number:  
Date of Protocol:   ALXN1840- HV-[ADDRESS_839199] 04526197 
28 April  2020 
[COMPANY_003]
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 2 of 61 
Alexion Confidential  INVESTIGATOR’S AGREE MENT  
I have read the study protocol and agree to conduct the study in accordance with this protocol, all 
applicable government regulations, the princi ples of the ICH E6 Guidelines for Good Clinical 
Practice, and the principles of the World Medical Association Declaration of Helsinki. I also 
agree to maintain the confidentiality of all information received or developed in connection with 
this protocol.  
  
 
 ____________________________________ 
Printed Name [CONTACT_7919]  
 
_____________________________________ 
Signature [CONTACT_7919] 
 _______________ 
Date
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 3 of 61 
Alexion Confidential  TABLE OF CONTENTS  
TITLE PAGE ...................................................................................................................................1  
INVESTIGATOR’S AGREE MENT  ...............................................................................................2  
TABLE OF C ONTENTS  .................................................................................................................3  
1. PROTOCOL SUMMARY  ............................................................................................7  
1.1. Synopsis ........................................................................................................................7  
1.2. Schema  ........................................................................................................................10  
1.3. Schedule of Activities  .................................................................................................11  
2. INTRODUCTION  ......................................................................................................14  
2.1. Study Rationale ...........................................................................................................14  
2.2. Background .................................................................................................................16  
2.3. Benefit/Risk Assessment  ............................................................................................16  
2.3.1.  Risk Assessment  .........................................................................................................16  
2.3.2.  Benefit Assessment  .....................................................................................................17  
2.3.3.  Overall Benefit: Risk Conclusion  ...............................................................................17  
3. OBJECTIVES AND ENDPOINTS  ............................................................................18  
4. STU DY DESIGN  .......................................................................................................19  
4.1. Overall Design  ............................................................................................................19  
4.2. Scientific Rationale for Study Design  ........................................................................20  
4.3. Justification for Dose  ..................................................................................................20  
4.4. End of Study Definition ..............................................................................................22  
5. STUDY POPULATION  .............................................................................................23  
5.1. Inclusion Criteria  ........................................................................................................23  
5.2. Exclu sion Criteria  .......................................................................................................24  
5.3. Lifestyle Considerations  .............................................................................................26  
5.4. Screen Failures  ............................................................................................................28  
6. STUDY INTERVENTION  ........................................................................................29  
6.1. Study Intervention Administered ................................................................................29  
6.2. Preparation/Handling/Storage/Accountability  ............................................................29  
6.3. Measures to Minimize Bias: Randomization and Blinding  ........................................30  
6.4. Study Intervention Compliance ..................................................................................30  
6.5. Concomitant Therapy .................................................................................................31  
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 4 of 61 
Alexion Confidential  6.5.1.  Allowed Medicine and Therapy .................................................................................31  
6.5.2.  Disallowed Medicine and Therapy  .............................................................................31  
6.6. Dose Modification  ......................................................................................................32  
6.7. Intervention After the End of the Study .....................................................................32  
7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  .......................................33  
7.1. Discontinuation of Study Intervention ........................................................................33  
7.2. Participant Discontinuation/Withdrawal From the Study  ...........................................[ADDRESS_839200]  .............................................................................38  
8.3.6.  Retained and Biobanked Sample ................................................................................39  
8.4. Treatment of Overdose  ...............................................................................................39  
8.5. Pharmacokinetics  ........................................................................................................39  
8.6. Pharmacodynamics .....................................................................................................40  
8.7. Genetics ......................................................................................................................40  
8.8. Biomarkers  ..................................................................................................................40  
8.9. Immunogenicity  ..........................................................................................................40  
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 5 of 61 
Alexion Confidential  8.10.  Health Economics and Medical Resource Utilization  ................................................40  
9. STATISTICAL CONSIDER ATIONS  .......................................................................41  
9.1. Statistical Hypotheses  .................................................................................................41  
9.2. Sample Size Determination  ........................................................................................41  
9.3. Populations for Analyses  ............................................................................................41  
9.4. Statistic al Analyses  .....................................................................................................41  
9.4.1.  Efficacy Analyses  .......................................................................................................42  
9.4.2.  Safety Analyses  ..........................................................................................................42  
9.4.3.  Other Analyses  ............................................................................................................42  
[IP_ADDRESS].  Pharmacokinetic and Pharmacodynamic Analyses ....................................................42  
9.5. Interim Analyses  .........................................................................................................44  
9.6. Data Mo nitoring Committee  .......................................................................................44  
9.7. Safety Review Committee ..........................................................................................44  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  ..................................................................................................45  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ....................45  
10.1.1.  Regulatory and Ethical Considerations  ......................................................................45  
10.1.2.  Financial Disclosure  ...................................................................................................45  
10.1.3.  Informed Consent Process ..........................................................................................46  
10.1.4.  Data Protection  ...........................................................................................................46  
10.1.5.  Dissemination of Clinical Study Data  ........................................................................47  
10.1.6.  Data Quality Assurance  ..............................................................................................47  
10.1.7.  Source Documents ......................................................................................................48  
10.1.8.  Study and Site Start and Closure ................................................................................48  
10.1.9.  Publication Policy  .......................................................................................................48  
10.2.  Appendix 2: Clinical Laboratory Tests .......................................................................50  
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ........................................................................52  
10.3.1.  Definition of AE  .........................................................................................................52  
10.3.2.  Definition of SAE  .......................................................................................................52  
10.3.3.  Recording and Follow-Up of AE and/or SAE ............................................................53  
10.3.4.  Reporting of SAEs ......................................................................................................54  
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 6 of 61 
Alexion Confidential  10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  .................................................................................................................56  
10.5.  Appendix 5: Abbreviations .........................................................................................[ADDRESS_839201] OF TABLES  
Table  1: Schedule of Activities  .................................................................................................11  
Table 2:  Potential Risks and Mitigation Strategy .....................................................................16  
Table  3: Study Design ...............................................................................................................20  
Table  4: Healthy Participant Lifestyle Considerations  .............................................................26  
Table  5: Details of Study Interventions Administered  .............................................................29  
Table  6: Populations for Analyses  ............................................................................................41  
Table  7: Protocol- Required Safety Laboratory Assessments  ...................................................50  
Table  8: List of Abbreviations and Definitions of Terms  .........................................................[ADDRESS_839202] O F FIGURES  
Figure 1:  Study ALXN1840- HV-105 Schematic .......................................................................10  
 
 
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 7 of 61 
Alexion Confidential  1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title: A Phase 1, Randomized, 2-Period, 2-S equence, Cross-over Study to Determine 
the Effect of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants . 
Short Title:  Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy 
Participants . 
Rationale:  
ALXN1840 is considered to have potential for moderate drug-drug interactions (DDI) due to 
inhibition of cytochrome P450 2C9 (CYP2C9) according to in vitro studies using human liver 
microsomes and simulations performed  to assess the potential for DDI risks. This study has been  
designed to determine the effect of ALXN1840 enteric -coated (EC) tablets at a single dose of 
60 mg (4 × 15 mg ) on the metabolism of celecoxib, a sensitive CYP2C9 substrate, at a single 
dose of 200 mg. A single dose of 60 mg ALXN1840 as a perpetrator is considered appropriate due to lack of potential for time -dependent inhibition (TDI) under the maximum observed 
ALXN1840 concentration in plasma after repeated daily dosing at steady state. A single dose of 
200 mg celecoxib as a victim is considered appropriate due to the linear pharmacokinetics (PK) of celecoxib within the approved therapeutic dose range.  
The 60 mg dose of ALXN1840 is the maximum allowed daily dose in the on-going Phase 3 
Study WTX101-301 in patients with Wilson disease (WD). The 200 mg celecoxib single dose 
has been selected based on the drug interaction study with fluconazole as described in the 
Celebrex
® [LOCATION_002] Prescribing Information (USPI) ( Celebrex® ) and Diflucan® USPI 
(Diflucan® ).  
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 8 of 61 
Alexion Confidential  Objectives and Endpoints  
Objectives  Endpoints  
Primary   
• To determine the effect of ALXN1840 on the 
PK of celecoxib, a sensitive CYP2C9 
substrate  • PK parameters of celecoxib ( maximum 
observed  plasma concentration [ Cmax], area 
under the plasma concentration (AUC) versus time curve from time [ADDRESS_839203] quantifiable 
concentration  [AUC
t], and AUC versus time 
curve from time 0  to infinity [AUC ∞]) with 
and without the coadministration of 
ALXN1840  
Secondary   
• To determine the effect of ALXN1840 on the 
PK of plasma molybdenum (Mo ) with the 
coadministration of celecoxib  
• To determine the safety and tolerability of ALXN1840, with the coadministration of celecoxib  • PK parameters for plasma total Mo (C max, 
AUC t, and AUC ∞) with the coadministration 
of celecoxib  
• Safety assessed by [CONTACT_629324] -emergent adverse event s (TEAEs) 
and treatment -emergent serious adverse 
event s (TESAEs) , physical examination, vital 
signs measurements, clinical laboratory and 
12-lead electrocardiogram  (ECG ) results  
Abbreviations: AUC ∞ = area under the plasma concentration  versus  time curve from time 0 to infinity; 
AUC t = area under the plasma concentration  versus  time curve from time [ADDRESS_839204] quantifiable concentration; 
Cmax = maximum observed  plasma concentration of the drug; CYP2C9 = Cytochrome P450 2C9; 
ECG  = electrocardiogram; Mo = molybdenum;  PK = pharmacokinetics; TEAE  = treatment -emergent adverse 
event; TESAE  = treatment -emergent serious adverse event.  
 
Overall Design 
This is a Phase 1, randomized, [ADDRESS_839205] of ALXN1840 on the metabolism of celecoxib, a sensitive CYP2C9 substrate, in healthy 
male and female participants. The safety and tolerability of ALXN1840 will be determined along 
with ALXN1840 PK in plasma as measured via total Mo with the coadministration of celecoxib.  
Disclosure Statement : This is an open -label, 2 -period, 2- sequence, cross-over study in healthy 
participants with randomization to 2 treatment sequences.  
Number of Participants : 
It is planned that approximately 38 participants will be enrolled at a single site.  
Intervention Groups and Duration:  
The study has a Screening P eriod  (Day  -28 to Day -2), two 11-day study periods (Day 1 to 
Day 11) with a minimum of 14 days between doses of celecoxib, and an End of Study (EOS) 
Visit (Day  15 ±  2 days) after Period 2 dosing. Participants will report to the clinical research unit 
(CRU) on the day prior (Day -1) to both dosing periods. In each study period, participants will receive one of the 2 treatments noted below:  
• Treatment A : One 200 mg celecoxib capsule with 240 mL water (fasting). 
• Treatment B : One 200 mg celecoxib  capsule + 4 × 15 mg ALXN1840 EC tablets 
with 240 mL water (fasting) . 
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 9 of 61 
Alexion Confidential  Participants will receive each treatment as a single dose administration in the sequence as 
defined below. 
Sequence 
number  Treatment sequence  Malea Femalea Total  
Study Period 1  Study Period 2  
1 A B 8 to 11  8 to 11  19 
2 B A 8 to 11  8 to 11  19 
Total  16 to 22 16 to 22  38 
a In an effort to achieve balance between males and females in each sequence, there will be no less than 16 and no 
more than 22 of either sex (ie, a maximum split in either direction of approximately 60%:40%). Randomization will 
be stratified by [CONTACT_4321].  
Treatment  A – One 200 mg celecoxib  capsule  with 240  mL water (fasting)  
Treatment B – One 200 mg celecoxib capsule  + 4 × 15 mg ALXN1840 enteric -coated tablets with 240  mL water 
(fasting)  
The time between dosing celecoxib alone or in combination with ALXN1840 in each treatment 
sequence will be a minimum of 14 days. Based on the estimated mean ALXN1840 half- life of 
approximately 2 days in healthy participants (under oral dose of 60 mg), a 14-day period 
between doses of celecoxib is considered sufficient to eliminate, on average, approximately more 
than 99.2% of the plasma total Mo before the next dose of celecoxib is administered. The mean 
elimination half-life (±SD) of celecoxib after chronic dosing is 11.2 (±  3.5) hours ( Celebrex® ), 
A 14 -day period between doses of celecoxib is sufficient to eliminate, on average, more than 
99.2% of the plasma celecoxib before the next dose of celecoxib is administered.  
Participants w ill return to the CRU on Day  15 (± 2 days) following Period  2 dosing for the EOS 
Visit with follow -up procedures, and to determine if any adverse events (AEs) have occurred 
since the last study visit. If participants withdraw from the study early, they will be seen and 
assessed by [CONTACT_079], and whenever possible, they are to undergo the procedures 
associated with the EOS Visit. Participants may be replaced at the discretion of Alexion.  
Participants may be asked or required to stay in the CRU between Periods 1 and 2, and/or before 
the EOS visit, for their own safety, and also to maintain the integrity of the conduct of the study. 
Data Monitoring Committee:  
There will not be a Data Monitoring Committee, but provision is included for an ad hoc Safety 
Review Committee, if needed.  
Original Protocol  28 Apr 2020  ALXN1840 -HV-105 
Page 10 of 61 
Alexion Confidential  1.2. Schema  
Figure  1: Study ALXN1840- HV-105 Schematic  
 
Participants will be admitted on Day  -1 of each period for C heck in procedures. Eligible participants will be 
randomized on Da y 1 immediately prior to dosing in Period  1. 
Participants will receive treatment (A or B) based on randomization on Day  1 of each period.  
Blood samples for PK analysis of total Mo (as a measure of ALXN1840) and celecoxib will be collected in each 
period on  Day 1 at pre -dose, 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours (Day 2) and then at 24 hour intervals on Days 3, 4, 5, 
6, 7, 8, 9, 10, and Day  11. The nominal 336-hour sample for Period 1  will be collected pre -dose in Period  2. 
Participants will be discharged on Day 11 of each period after completion of all procedures and review of all safety 
data. The end of study visit (EOS) will occur on Day  15 ± 2 of Period  2, with the collection of 336 -hour PK sample 
for Period 2 . 
Participants may be asked or re quired to stay in the CRU between Periods 1 and 2, and/or before the EOS visit, for 
their own safety, and also to maintain the integrity of the conduct of the study.  
 

Original Protocol 28 Apr 2020 
 ALXN1840 -HV-105 
Page 11 of 61 
Alexion Confidential  1.3. Schedule of Activities  
Table  1: Schedule of Act ivities  
Study Procedures  Sa C-Ib Treatment Periods 1 and 2  EOS or ETc 
Days → -28 
to -2 -1 1 2 3 4 5 6 7 8 9 10 11 15 (±2)  
Hours →    Pre-
dose  0d 1 2 3 4 5 6 8 12 24  48 72 96 120 144 168 192 216 240 336e 
Eligibility  
Informed consent  x                       
Inclusion/exclusion criteria  x x                      
Pregnancy test  x x                     x 
Urine a lcohol test  x x                      
Urine drug screen  x x                      
HIV, hepatitis B and C 
screen  x                       
Study Administrative  
Medical 
history/demographicsf x                       
Physical examinationg x x                     x 
Weight  x x                      
Height and BMI  x                        
Discussion/documentation 
of contraception method  x x                      
Randomization     xh                    
Administration of Study Interventioni  
Treatment A: celecoxib or 
Treatment B: celecoxib + 
ALXN1840     x                    
PK Blood Sample  
Celecoxib and ALXN1840 
PK    x  x x x x x x x x x x x x x x x x x x x 
Pharmacogenetic sample  
CYP2C9 genotypi[INVESTIGATOR_007]   x                      
Original Protocol 28 Apr 2020 
 ALXN1840 -HV-105 
Page 12 of 61 
Alexion Confidential  Table  1: Schedule of Activities (Continued)  
Study Procedures  Sa C-Ib Treatment Periods 1 and 2  EOS or ETc 
Days → -28 
to -2 -1 1 2 3 4 5 6 7 8 9 10 11 15 (±2)  
Hours →    Pre-
dose  0d 1 2 3 4 5 6 8 12 24  48 72 96 120 144 168 192 216 240 336e 
Laboratory Assessments   
Chemistryj, hematology, 
coagulation  x x           x   x     x  x 
Follicle stimulating 
hormonek  x                       
Urinalysis  x x                      
Vitals signs measurements  x  x  x   x   x x x          x 
12-Lead ECGl x  x     x                
Retained sample (safety)m   x                      
AE monitoring and 
concomitant therapi[INVESTIGATOR_629315]   
a Within [ADDRESS_839206] 10  hours prior to study intervention . 
c Participants are required to return to the  CRU approximately Day  15 (±  2 days) following the final dose of study medication for an EOS evaluation.  
Participants may be asked or required to stay in the CRU between Periods 1 and 2, and/or before the EOS visit, for their own safety, and also to maintain the 
integrity of the conduct of the study.  In the event of early termination/discontinuation  (ET) , the procedures listed at the EOS are performed prior to participant 
discharge .   
d Hour  0 corr esponds to the time of celecoxib  ± ALXN1840 administration. Unless stated otherwise, times listed are in relation to celecoxib  ± ALXN1840 
dosing. 
e The nominal 336-hour sample for Period 1 to be collected pre dose in Period 2.  
f Parameters include age and sex. Race and ethnicity will be collected where permitted by [CONTACT_427].  
g A full physical examination will be performed at Screening, Check -in for each period, and at the end of the study or upon ET. A symptom -driven physical 
examination may be performed at other times, at the PI’s discretion . 
h Randomization will occur before dosing . 
i Each dose administration will be separated by [CONTACT_2669] [ADDRESS_839207] dose 
chemistry, fasting is not required (Section  10.2). 
k Only needed if claiming exemption from contraception requirement due to menopause.  
Original Protocol [ADDRESS_839208]- dose (before lunch) on Day  1. ECGs will be conducted before PK blood 
sampling if these 2 events  are scheduled to  occur at the same time.  
m A single 15 mL sample will be retained for evaluation in the event of an unexpected safety finding; retained samples may be destroyed after completion of the 
clinical study report.  The retained serum sample will only be collected pre -dose on Day 1 of Period 1.  
 
Abbreviations: AE  = adverse event; BMI  = body mass index; C -I = Check -in; CRU  = clinical research unit; ECG  = electrocardiogram; EOS  = End of Study; 
ET = Early Termination; FSH  = follicle -stimulating hormone; HIV  = human immunodeficiency virus; HR  = heart rate; PI  = Principal Investigator; 
PK = pharmacokinetics; S  = Screening.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 14 of 61 
Alexion Confidential  2. INTRODUCTION  
ALXN1840 (bis-choline tetrathiomolybdate; formerly known as WTX101) is a novel, 
first- in-class, copper (Cu)-protein binding agent in development for the treatment of Wilson 
disease (WD) and primary biliary cholangitis (PBC).  
2.1. Study Rationale  
This study is being conducted to determine the effect of ALXN1840 at a single dose of 60 mg on 
the metabolism of celecoxib, a sensitive cytochrome P450 2C9 (CYP2C9) substrate, at a single dose of 200 mg ( Celebrex® ). ALXN1840 is considered to have the potential for weak to 
moderate drug-drug interactions (DDI) due to inhibition of CYP 2C9, according to in vitro 
studies conducted using human liver microsomes and simulations performed to assess DDI risks (Study CYP0840-R2, Study 1907124 and Study AXP/1/B). This study has been designed and 
will be conducted in accordance with the current regulatory guidance issued by [CONTACT_629325] (FDA) “Clinical Drug Interaction Studies — Cytochrome P450 Enzyme - 
and Transporter- Mediated Drug Interactions” (2020), European Medicines Agency (EMA)  
Committee for Medicinal Products for Human Use “Guideline on the Investigation of Drug 
Interaction” (2012), and the Japan Pharmaceuticals and Medical Devices Agency  (PMDA)  
“Guideline on drug interaction for drug development” (2019 ). 
Based on a mean ALXN1840 maximum observed plasma concentration (C
max) value of 3.92 μM  
with a single dose of 60 mg enteric -coated (EC) tablet under fasting conditions in healthy 
participants (Study WTX101-102), a steady state plasma total Mo Cmax of 13.03 μM can be 
estimated , considering accumula tion ratio of 3.33 with linear pharmacokinetics (PK). In the 
Phase [ADDRESS_839209] plasma total 
molybdenum ( Mo) concentration was 20.3 µM  after repeated doing of ALXN1840 at 60 mg; the 
dose was escalated to 120  mg at Week 4. Assuming all tetrathiomolybdate (the active ingredient 
in ALXN1840) in human plasma is free (a conservative appro ximation  since 90% - 95% of the 
total Mo in plasma is bound to copper and albumin by [CONTACT_629326] ), there is no 
potential that ALXN1840 may induce cytochrome P450 (CYP) isoforms or inhibit p-glycoprotein, breast cancer resistance protein, or the organic anion and organic cation uptake transporters. However, as the estimated in vivo steady- state plasm a levels of total Mo after 
dosing ALXN1840 at 60 mg (13.03 µM) daily may exceed the drug concentration required to 
produce 50% of the maximal inhibition (IC
50 value = 6.9 µM ) of CYP2C9 in vitro, a moderate 
potential for inhibition of CYP2C9 was theoretical ly and conservatively anticipated  
(Study 030519b, Study 030709c, Study MC05063, and Study CYP0840- R2). 
Subsequent i n vitro studies in human liver microsomes (HLM) have shown a potential inhibitory 
effect (competitive and time -dependent) of ALXN1840 (and possibly its degradation products) 
on CYP2C9 -mediated metabolism (Study CYP0840- R2 and Study 1907124). The IC [ADDRESS_839210] on CYP2C9 was observed at 6.9 µM (3.0  µg/mL) with the estimated Ki 
values of 6.07 µM ( 2.6 µg/mL; Study CYP0 840-R2 and Study AXP/1/B). Furthermore, the study 
(Study 1907124) specifically examining the inactivation potential of ALXN1840 on CYP2C9 catalytic activity in vitro using HLM and the FDA recommended CYP2C9 probe substrate 
diclofenac 4' -hydroxylation with the time -dependent probe inhibitor  tienilic acid  as active control 
(US Food and Drug Administration), demonstrated potential for time -dependent inhibition (TDI) 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 15 of 61 
Alexion Confidential  at ALXN1840 concentrations ≥ 30 µM. Because the maximum observed plasma total Mo 
concentration in the Phase 2 Study WTX101-201, conducted in patients with WD, was 20.3 µM 
after repeated doing of ALXN1840 at 60 mg and then dose- escalated to 120  mg at Week  4, the 
observed in vitro TDI potential at ALXN1840 concentration of ≥ 30 µM is not antici pated in 
vivo, even considering total Mo of 20.3 µM is 100% active and free ALXN1840 (a most conservative case) . Assuming 10% of the total Mo is in the form of free and active ALXN1840, 
which is still conservative given that most of this 10% are likely ALXN1840 degradants such as 
molybdate, then the highest anticipated individual free and active ALXN1840 concentration is at 
2.03 μM in patients with WD, when dosed at 120 mg daily at steady state . Overall , this, implies a 
negligible  possibility for observing in vivo TDI with repeated daily doses of ALXN1840 at 60 
mg or up to 120 mg in patients with WD . 
Finally, a validated Simcyp® physiologically based pharmacokinetic model, developed using 
data from Study WTX101- HV-106, predicted a weak CYP2C9 inhibition potential for 
simulations of single dose ALXN1840 exposures at [ADDRESS_839211] simulated single dose of 240 mg ALXN1840 ( Study AXP/1/B), indicating weak  inhibitory potential in  vivo  (weak for AUC ratio 
of ≥ 1.25- to < 2 -fold), per the 2020 FDA guidance on “ Clinical Drug Interaction Studies — 
Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions”. For the highest simulated single dose of [ADDRESS_839212] with CYP2C9 is estimated at 4.1  µM, after accounting for the 
formation of tetrathiomolybdate -Cu-albumin t ripartite complexes ( TPC), which is higher than 
the 2.03 µM noted above. 
Overall, based on in vitro and in silico study results, the maximum total daily doses in clinical 
studies (currently 60 mg in Phase 3 Study WTX101-301, but previously up to 120 mg in Phase 2 
Study WTX101- 201) are not anticipated to reach steady -state ALXN1840 concentrations 
associated with TDI. According to the FDA guidance (US FDA “Clinical Drug Interaction 
Studies - Cytochrome P450 Enzyme - and Transporter- Mediated Drug Interactions” [2020]), a 
single dose study design using the highest anticipated clinically  relevant dose will be appropriate 
and justified if there is no TDI. Therefore, single dose of ALXN1840 at [ADDRESS_839213] abundant drug metabolizing cytochrome P450 2C subfamily enzyme in the human liver, and accounts for approximately 20% of total hepatic P450 protein with mass spectrometry quantitation. Common substrates of CYP2C9 include, but are not limited to, 
numerous NSAIDs, oral hypoglycemic agents, including tolbutamide and sulfonylure as, 
angiotensin II blockers, rifampi[INVESTIGATOR_629316] S -warfarin. In all, CYP2C9 covers the metabolism of 
approximately 15% of drugs that involve CYP450 enzymes ( Daly, 2017;  Dean, 2012). 
The potentially weak to moderate inhibitory effects of a single [ADDRESS_839214] a very limited safety concern based on the Celebrex
® USPI (Celebrex® ).  
Further details of the currently available drug metabolism, pharmacokinetics, and safety data are available in the Investigator’s Brochure (IB) for ALXN1840 (Edition 10, 25 Feb 2020).  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 16 of 61 
Alexion Confidential  2.2. Background 
ALXN1840 is in development for the treatment of WD and PBC due to its improv ed stability 
prope rties over ammonium te trathiomolybdat e, the latter of which has previously been studied in 
patients with WD and other indications . Ammonium tetrathiomo lybda te as we ll as 
bis-c holine  tetrathiomo lybdate non-c linical and c linical data  reported to date support therapeutic 
efficacy and with an appropriate safety profile for ALXN1840.  
ALXN1840 rapi[INVESTIGATOR_629317], which stabilize free and potentially toxic Cu leading 
to a reduction in the non- ceruloplasmin -bound Cu (NCC) concentrations or NCC corrected for 
TPC [NCC corrected ]) (Weiss, 2017). 
Detailed descriptions of the chemistry, pharmacology, efficacy, and safety of ALXN1840 are provided in the IB for ALXN1840.  
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably expected adverse events (AEs) for ALXN1840 may be found in the IB and for celecoxib in the 
prescribing information (Celebrex® ). 
2.3.1. Risk Assessment  
Details of the potential risks and mitigation strategy are provided in Table 2 .  
Table 2:  Potential Risks and Mitigation Strategy  
Potential Risk of Clinical 
Significance  Summary of Data/Rationale for 
Risk  Mitigation Strategy  
ALXN184 0 
Dose -dependent elevations in 
transaminases (ALT and AST)  Generally mild to moderate in 
severity, asymptomatic and 
reversible with dose adjustments 
were reported, usually after 
3 – 6 weeks of treatment in patients 
with WD 
 Regular monitoring of liver 
function tests  
Anemia  Anemia has been observed in 
patients with WD, PBC and cancer, and attributed to overtreatment and 
resultant Cu depletion  Monitoring complete blood count  
Low white blood cell count 
(leukopenia, bone marrow toxicity)  Leukopenia and bone marrow 
toxicity (myelosuppression) have been observed in patients with WD 
and attributed to overtreatment and 
resultant Cu depletion  
 Monitoring complete blood count   
Study  Procedures  
Risks associated with the study 
design and procedures  Participants will undergo repeated 
blood draws to measure the PK of 
the study intervention and 
metabolism. Blood draws may result in ecchymosis, redness and 
minor pain to the site. On rare  Blood draws are optimized for PK. 
A cannula may be placed to 
minimize needle sticks  
Original Protocol [ADDRESS_839215] benefit to study participants.  
2.3.3. Overall Benefit: Risk Conclusion  
Taking into account the measures implemented to minimize risk to participants, the potential 
risks identified in association with ALXN1840 and celecoxib are justified by [CONTACT_629327].  occasion, infection or 
thrombophlebitis can occur  
Celecoxib  
As per prescribing information  Celecoxib prescribing information 
(Celebrex® ) Participants will be monitored for 
adverse réactions  and by [CONTACT_629328]. Participants 
may be discontinued for significant 
drug related adverse events  
Abbreviations: ALT  = alanine aminotransferase; AST  = aspartate aminotransferase; Cu  = copper; 
IB = Investigator’s Brochure; PBC = primary biliary cholangitis; PK = pharmacokinetics; 
WD = Wilson  Disease . 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 18 of 61 
Alexion Confidential  3. OBJECTIVES AND ENDPO INTS  
Objectives  Endpoints  
Primary   
• To determine the effect of ALXN1840 on the 
PK of celecoxib , a sensitive CYP2C9  
substrate  • PK parameters of celecoxib (C max, area under 
the plasma concentration (AUC) versus time 
curve from time [ADDRESS_839216] quantifiable 
concentration  [AUC t], and AUC versus time 
curve from time 0  to infinity [AUC ∞]) with 
and without the coadministration of 
ALXN1840  
Secondary   
• To determine the effect of ALXN1840 on the 
PK of plasma Mo with the coadministration of celecoxib  
• To determine the safety and tolerability of 
ALXN1840, with the coadministration of 
celecoxib  • PK parameters for plasma total Mo (C max, 
AUC t, and AUC ∞) with the coadministration 
of celecoxib  
• Safety assessed by [CONTACT_65102] -
emergent adverse event s (TEAEs) and 
treatment -emergent serious adverse event s 
(TESAEs) , physical examination, vital signs 
measurements, clinical laboratory and 12 -lead 
electrocardiogram  (ECG ) results   
Abbreviations: AUC ∞ = area under the plasma concentration  versus  time curve from time 0 to infinity; 
AUC t = area under the plasma concentrat ion versus  time curve from time [ADDRESS_839217] quantifiable concentration; 
Cmax = maximum observed  plasma concentration of the drug; CYP2C9 = cytochrome P450 2C9; 
ECG  = electrocardiogram; PK  = pharmacokinetics; TEAE  = treatment -emergent adverse event; 
TESAE  = treatment -emergent serious adverse event.  
Original Protocol [ADDRESS_839218] of a single dose of ALXN1840 (perpetrator) on the single dose celecoxib 
(victim) kinetics in healthy male and female participants.  
The study has a Screening period (Day  -28 to Day -2), two 11- day study periods (Day  1 to 
Day 11) with a minimum of 14  days between  doses of celecoxib , and an End of Study (EOS) 
Visit (Day  15 ±  2 days) after Period  2 dosing. Participants will report to the clinical research unit 
(CRU) on the day prior (Day -1) to both dosing periods. 
All participants will receive 1  treatment in each study period; treatment order will be defined 
based on randomization:  
• Treatment A : One 200 mg celecoxib  capsule with 240 mL water (fasting). 
• Treatment B : One 200 mg celecoxib capsule + 4 × 15 mg ALXN1840 E C tablets 
with 240 mL water (fasting) . 
Based on randomization, participants will be administered either Treatment A or Treatment B in 
each period. A wash -out period of at least [ADDRESS_839219]- dose to ensure full assessment of exposure over 
time. The nominal 336-hour sample for Period  1 is pre -dose sample for Period  2. In addition to 
PK sampling, safety and tolerability will be assessed by [CONTACT_42466], vital signs, 12- lead 
electrocardiograms (ECGs), and laboratory parameters.  
Following scheduled procedures on Day  11, participants will be discharged from the unit. If 
there are any participants with clinically significant abnormalities at the time of discharge, the Investigator should notify the Medical Monitor prior to discharge, and participants may be asked to remain institutionalized for further clinical monitoring.  
Participants may be asked or required to stay in the CRU between Periods 1 and 2, and/or before the EOS visit, for their own safety, and also to maintain the integrity of the conduct of the study. 
The End of Study (EOS) Visit will occur approximately 4  days after discharge from Period  2, 
after collection of the nominal 336-hour PK sample.  
This study will include approximately 38 participants; the overall study population will include a minimum of 40% of each sex.  
Participants will be randomized to one of two sequences as described in Table  3. 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 20 of 61 
Alexion Confidential  Table  3: Study Design  
Sequence 
Number  Treatment Sequence  Malea Femalea Total  
Study Period 1  Study Period 2  
1 A B 8 to 11 8 to 11 19 
2 B A 8 to 11 8 to 11 19 
Total  16 to 22 16 to 22 38 
aIn an effort to achieve balance between males and females in each sequence, there will be no less than 16 and no 
more than 22 of either sex (ie, a maximum split in either direction of approximately 60%:40%). Randomization will 
be stratified by [CONTACT_4321].  
Treatment  A -One 200  mg celecoxib capsule with 240  mL water (fasting)  
Treatment B – One 200  mg celecoxib capsule  + 4 × 15 mg ALXN1840 enteric -coated tablets with 240  mL water 
(fasting)  
At the Investigator’s discretion, additional participants may be screened t o allow for a full 
enrollment of the study, with a minimum of 40% for each sex. Therefore, it is possible that all 
eligible participants may not be included. Participants not included in the study will be discharged without dosing on Day 1. 
4.2. Scientific Rationale for Study Design 
This study is being conducted in healthy participants so that the assessments are not confounded by [CONTACT_259118], comorbidities, or concomitant medications. The inclusion and exclusion criteria for this study are c onsistent with Phase  [ADDRESS_839220] of sequence of administration, the study is 
being conducted as a 2-sequence, 2-period cross-over study. Blood sampling for PK assessment 
will include measures for ALXN1840 and celecoxib. Blood sampling timepoints support evaluation of time to reach maximum observed plasma concentration (T
max) and C max and include 
a minimum of [ADDRESS_839221] 14  days, based on the 
estimated mean half -life for AL XN1840 of approximately 2 days as previously reported in the 
bioavailability studies ( Studies WTX101-101 and WTX101-102) , where healthy participants 
took an oral dose at 60 mg. Therefore, a minimum of 14  days between dose administration is 
considered sufficient to eliminate, on average, approximately more than 99.2% of the plasma 
total Mo before a second dose of celecoxib. The approximately 4- day interval after Period  [ADDRESS_839222] eliminated measurab le 
concentrations of ALXN1840 at the EOS Visit regardless of the randomized dosing sequence. The mean elimination half-life (±SD) of celecoxib after chronic dosing is 11.2 (±  3.5) hours 
(Celebrex® ), therefore a minimum of 14 -day interval between single dose administrations is 
sufficient to eliminate greater than 99 .2% of plasma celecoxib .  
4.3. Justification for Dose  
ALXN1840  
The maximum tolerated dose (MTD) of ALXN1840 is unknown. To date, the [ADDRESS_839223] an acceptable safety profile in humans as 
demonstrated in the completed bioavailability studies th at were conducted in healthy male and 
female participants (Study  WTX101-101 and Study WTX10 1-102) with a median (range)  body 
weight of 80.8 kg (57.6 to 107.0 kg) as well as the completed Study  WTX101-201, conducted in 
patients with WD.  
Tetrathiomolybdate  reacts with albumin -bound Cu in the liver or blood to form a stable tripartite 
complex which is excreted into the bile. Tetrathiomolybdate which does not bind to Cu and 
albumin, is not metabolized by [CONTACT_629329], 
which is excreted in the urine. Therefore, findings from the human microsome study 
(Study CYP0840- R2) are considered  an over-estimation of the effect to be observed in vivo. 
Given that in vitro in hibition was observed with the ALXN1840 parent drug and no apparent 
accumulation of free ALXN1840 as part of the plasma ultrafiltrate (PUF) Mo or non -TPC-bound 
Mo after ALXN1840 repeated dosing (preliminary results from Study WTX101-201), a single 
dose of ALXN1840 is considered to be sufficient to assess the  inhibition  potential of CYP2C9 
using celecoxib as the substrate. Single dose administration of the ALXN1840 tablet under fasted 
conditions resulted in a peak drug concentration of total Mo at approximately 4.54 hours, with a half-life of approximately 51 hours (Study WTX101-102).  
Celecoxib  
Peak plasma levels of celecoxib occur approximately [ADDRESS_839224] not been conducted for this drug . Celecoxib 
exhibits a dose proportional increase in exposure after oral administration up to 200 mg twice 
daily and less than proportional increase at higher doses. It has extensive distribution and high protein binding with a half- life of approximately 11  hours ( Celebrex® ). 
Celecoxib metabolism is predominantly mediated via CYP2C9 in the liver. Concomitant 
administration of fluconazole 200 mg and celecoxib 200 mg resulted in a 2- fold increase in 
celecoxib plasma concentration. This increase is due to the inhibition of celecoxib metabolism 
via CYP2C9 by [CONTACT_251186]. For celecoxib, the selected dose in this study is 200 mg, which has 
been selected based on the drug interaction study with fluconazole in the Celebrex
® US package 
insert (Celebrex®) and Diflucan® USPI (Diflucan® ). A single dose is considered appropriate due 
to the linear PK of celecoxib within the approved therapeutic dose range.  
Celecoxib is formulated into capsules at 50, 100, 200, and [ADDRESS_839225] dose withi n the linear range of the drug to allow DDI 
assessment (linear PK is thought to be limited by [CONTACT_629330] 200 mg). Even though 
ALXN1840 is considered theoretically and conservatively to have potential for moderate 
inhibition of CYP2C9 in vitro, b ecause this study is being conducted as a single dose study , 
without risk of accumulation, no dose adjustment is being made to the dose of celecoxib. A dose of [ADDRESS_839226] completed the study if he/she has completed all phases of the 
study including the last scheduled procedure shown in the Schedule of Activities (SoA). 
The end of the study is defined as the date the last participant completes the last visit as shown in 
the SoA ( Table  1). 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 23 of 61 
Alexion Confidential  5. STUDY POPULATION  
Prospective app roval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant s must be 18 to 50 years of age inclusive, at the time of signing the informed 
consent. 
Type of Participant and Disease Characteristics 
2. Participants who are healthy as determined by [CONTACT_629331], physical examination, vital signs, 12- lead ECG, and clinical laboratory 
evaluation (hematology, biochemistry, coagulation, and urinalysis) that are reasonably likely to interfere with the participant ’s participation in or ability to complete the study, 
or to potentially confound interpretation of study results, as assessed by [CONTACT_737].  
3. Adequate venous access in the left or right arm to allow collection of a number of blood samples.  
Weight 
4. Body weight ≥ 45 to ≤ 100  kg and body mass index (BMI) within the range of 18 to 
< 30 kg/m
2 at Screening.  
Sex 
5. Contraceptive use by [CONTACT_288941].  
a. Male Participants:  
• Male participants, if heterosexually active with a female spouse or partner of 
childbearing potential or a pregnant or breastfeeding spouse or partner, must agree to 
use barrier contraception (male condom) for the duration of the study and for at least 3 months after the end of systemic exposure of the study intervention  (ie, 3  months 
after the EOS Visit). Male participants must also agree to not donate sperm for at 
least 3  months after the end of systemic exposure of the study intervention  (ie, 
3 months after the EOS Visit).  
• Female spouses or partners of male participants who are of childbearing potential must use highly effective contraception as defined below and in Section 10.[ADDRESS_839227] 1  menstrual cycle before (the male participant’s) first study 
intervention administration and continuing until at least 3 months after the end of their male partner’s systemic exposure to the study intervention (ie, 3  months after the 
EOS Visit).  
• Barrier contraception is required even with documented medical assessment of surgical success of a vasectomy. For male participants who have had a vasectomy 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 24 of 61 
Alexion Confidential  (with documented evidence of azoospermia if  possible) and agree to use a barrier 
method (male condom) for the stated time period, no additional contraceptive method 
is required by [CONTACT_288942].  
b.  Female Participants:  
• Female participants or female partners of male participants of childbearing  potential, 
(including breastfeeding females), if heterosexually active, must be willing to follow 
protocol- specified contraception guidance starting at least [ADDRESS_839228] 3 months after the 
end of systemic exposure of the study intervention  (ie, 3  months after the EOS Visit). 
Female participants must not donate ova for at least 3  months after the EOS (ie , 3 
months after the EOS Visit).  
• Female participants who are documented  as being of non-childbearing potential as 
defined in Section  10.4 are exempt from contraception requirements.  
• Highly effective contraceptive methods for female  participants and female partners of 
male participants  are described in Section  10.4.  
• Women of childbearing potential  must have a negative h ighly sensitive serum  
pregnancy test at screening . Additional urine pregnancy testing will be standard for 
the protocol unless serum testing is required by [CONTACT_288926], local regulation, or IRB/IEC and should be performed per the time points specified in the SoA ( Table  1). 
Informed Consent  
6. Capable of giving signed informed consent as described in Section  10.1.3, which includes 
compliance with the requirements and restrictions listed in the informed consent form 
(ICF) and in this protocol.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. History or presence of/significant history of or current cardiovascular, respi[INVESTIGATOR_696], hepatic, 
renal, gastrointestinal, endocrinological, hematological, or neurological disorders. Participants with a history of gastric by[CONTACT_6476], other surgical procedure, or medical condition that may significantly alter absorption of drugs.  
2. Clinically significant multiple or severe drug allergies, food allergies , or allergies to study 
product or class of product or its derivatives.  
3. Lymphoma, leukemia, or  any malignancy within [ADDRESS_839229] 10  years.  
5. Serum creatinine > upper li mit of normal (ULN) of the reference range of the testing 
laboratory at Screening or on Check -in Period 1.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 25 of 61 
Alexion Confidential  6. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin >  ULN 
of the testing laboratory at Screening and Check-in. Part icipants with confirmed Gilbert’s 
syndrome may be included with total bilirubin > ULN but below 3 × ULN if participant has a 
measured direct bilirubin < ULN.  
7. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the 
exception of Gilbert’s syndrome or asymptomatic gallstones). 
8. QTc > 450 msec for male participants or >  470 msec for female participants  
NOTE A: The QTc is the interval between the start of the Q -wave and the end of the T- wave 
in an ECG (QT interval) corrected for heart rate according to Bazett’s formula (QTcB), Fridericia’s formula (QTcF), and/or another method. It is machine -read with Investigator 
review.  
NOTE B: The specific formula used to determine eligibility and discontinuation  for an 
individual participant should be determined prior to initiation of the study; QTcF is preferred; however, QTcB may be used if QTcF cannot be measured. 
Prior/Concomitant Therapy  
9. Use or intended use of prescription medications (excluding oral contraceptives) within 14 days or 5 half-lives of the drug (whichever is longer) prior to dosing on Day 1, except 
with prior approval of Alexion. Participants may not have a medical condition that requires 
chronic medicinal therapy.  
10. Use of nonprescription/ over- the-counter medications, including COX-2 inhibitors, herbal 
remedies and supplements, within 7  days prior to dosing on Day 1 and/or intended use at any 
point over the duration of the study.  
Prior/Concurrent Clinical Study Experience  
11. Participation in  a study resulting in loss of blood or donation of blood products in excess of 
[ADDRESS_839230] dose administration.  
Diagnostic assessments  
14. Presence of hepatitis B surface antigen (HBsAg) at Screening or within [ADDRESS_839231] dose of s tudy intervention. Presence of HBsAg or positive hepatitis C antibody or 
ribonucleic acid (RNA) test result at screening or within [ADDRESS_839232] dose of study 
intervention.  
• NOTE: Participants with positive hepatitis C antibody due to prior resolved disease 
can be enrolled if a confirmatory negative hepatitis C RNA test is obtained.  
• NOTE: The RNA test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing. 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 26 of 61 
Alexion Confidential  15. Positive pre -study alcohol or drugs of abuse screen. 
16. Positive human immunodeficiency virus (HIV) antibody test.  
17. Ongoing use of tobacco products or nicotine delivery systems. 
Other Exclusions 
18. Regular alcohol consumption within 6 months prior to the study defined as: an average 
weekly intake of > 14 units/week for males or >  7 units/week for females. One unit is 
equivalent to 8 g of alcohol: a half pi[INVESTIGATOR_11731] (~240 mL) of beer, one ~4 oz glass (125 mL) of wine 
or 1 (25 mL) measure of spi[INVESTIGATOR_2120].  
19. Regular use of known drugs of abuse , based on the assessment of the investigator.  
20. Prior exposure to ALXN1840 or other tetrathiomolybdate salt. 
21. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy 
that, in the opi[INVESTIGATOR_24245], contraindicates participation in 
the study.  
22. History of a sthma or history of allergy to NSAIDs . 
5.3. Lifestyle Considerations  
Participants must be able and willing to adhere to the following lifestyle restrictions  
Table  4: Healthy Participant Lifestyle Considerations  
Items Participants Must Not 
Consume or Do  When Participants Must Stop  When Participants Can Restart  
Tobacco in any form (eg, smoking 
or chewing) or other nicotine -
containing products in any form 
(eg, gum, patch, electronic 
cigarettes or vaporized inhalation 
device)  From Screening  After the final study visit  
Alcohol  48 hours before check -in to the 
CRU (Day -1) and until discharge 
(Day 11), and 48 hours before the 
EOS Visit  Discharge from the clinical research 
unit and completion of EOS visit  
Meals/snacks/water  
 Breakfast will be omitted on the 
Day of dosing (Day 1). With the exception of  the day of dosing, 
water/fluids may be consumed ad 
libitum. On the day of dosing, 
participant must refrain from water intake from [ADDRESS_839233] meals will be provided 
during institutionalization  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 27 of 61 
Alexion Confidential  Table  4: Healthy Participant Lifestyle Considerations (Continued) 
Items Participants Must Not 
Consume or Do  When Participants Must Stop  When Participants Can Restart  
Not consume any other substances 
known to be potent inhibitors or 
inducers of CYP450 enzymes. This 
inclu des food or drink products 
containing cranberry, pomegranate, 
star fruit, grapefruit, pomelos, 
exotic citrus fruits or Seville oranges (including marmalade and 
juices made from these fruits). Red 
wine should also not be consumed  Within [ADDRESS_839234] study intervention administration  After collection of the final PK 
sample for each study period  
Caffeine -containing or xanthine -
containing products (eg, tea, coffee, cola drinks, and chocolate)  During each dosing period, 
[ADDRESS_839235] 
study intervention administration 
and each outpatient/ follow -up visit  After collection of the final PK 
sample for each study period  
Strenuous physical activity  Starting 72  hours prior to each 
blood collection for clinical laboratory tests. Participants may 
participate in light recreational activities during studies (eg, 
watching television, reading)  After study completion/last visit. 
Participants should not start new 
physical training activities during 
the study until study  completion 
(last visit)  
Any prescription medication. For 
details, see Section  5.2  
Note: If participants have a medical 
need to take any medication or have 
any medications prescribed to them by a doctor, they should follow the 
medical advice but inform the 
Investigator as soon as possible 
afterwards. Participants should be 
informed not to stop taking any 
medication that has been prescribed 
by [CONTACT_629332]  14 days or 5  half-lives prior to 
dosing on Day 1 After the final study visit  
Any nonprescription/ 
over-the-counter medi cation, 
including herbal remedies and supplements . For details, see 
Section  
5.2.  Use of nonprescription/ 
over-the-counter medications, 
within 7  days prior to dosing on 
Day 1 and/or intended use at any 
point over the duration of the study.  
With Investigator approval, 
participants may take up to 
1000  mg/day of acetaminophen  After the final study visit  
Any herbal remedy or dietary 
supplement containing St John’s 
Wort  [ADDRESS_839236] 
study intervention administration  After study completion/last visit  
Blood and plasma donation  Participation in a study resulting in 
loss of blood or donation of blood 
products in excess of 500 mL 
within 60  days prior to Day  1 
(Section  5.2) 1 month after study completion/last 
visit 
Original Protocol [ADDRESS_839237] comply with the 
appropriate contraceptive 
requirements as stated in 
Section  10.4 Start times for contraceptives vary 
according to method used (see applicable contraceptive method in 
Section  10.4) See Section  10.4 
Abbreviations: CYP450  = cytochrome P450; PK  = pharmacokinetics.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen  failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details (eg, failed eligibility cr iteria), and any AEs, including any serious adverse 
events (SAEs) and any related concomitant medication,  occurring during the screening period. 
Individuals who do not meet the criteria for participation in this study (screen failure) due to a reason that is expected to resolve or has resolved, may be rescreened based on discussion and 
agreement between the Investigator and the Medical Monitor.  
 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 29 of 61 
Alexion Confidential  6. STUDY INTERVENTION  
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the 
study protocol. 
6.1. Study Intervention Administered 
Details of the study interventions administered in the study are provided in Table  5. 
ALXN1840 and celecoxib will be administered at the morning of Day 1. 
Table  5: Details of Study Interventions Administered  
ARM Name  [CONTACT_629347]1840 (formerly WTX101)  Celecoxib  
Type  Drug  Drug  
Dose 
Formulation  Tablet  Capsule  
Unit Dose 
Strength(s)  15 mg ALXN1840  200 mg 
Dosage Level(s)  Single dose 60  mg administered as 
4 × 15 mg ALXN1840 tablets  Administered as a single dose (1  × 200 mg 
capsule)  
Route of 
Administration  Oral Oral  
Use experimental/study intervention  comparator/reference  
IMP and NIMP  IMP  IMP 
Sourcing  Provided centrally by [CONTACT_629333]1840 will be provided in treatment 
kits that will each have a unique 
identification number and be packaged and 
labelled in accordance with all applicable 
regulatory requirements. At a minimum, the treatment kit label will provide the 
following information: study Sponsor identification, batch number, directions for use, required storage conditions, caution 
statements (including “New Drug -Limited 
by [CONTACT_12201]” 
language), study identification, and expi[INVESTIGATOR_629318]/Former 
Name(s) or 
Alias(es)  Sponsor’s  name  - Bis-choline 
tetrathiomolybdate   
[LOCATION_003]N  - Tiomolibdate choline  Celebrex  
Abbreviations: IMP  = investigational medicinal product; NIMP  = noninvestigational medicinal product ; 
[LOCATION_003]N  = [LOCATION_002] adopted name  
6.2. Preparation/Handling/Storage/Accountability  
1. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer the s tudy intervention. All study 
intervention must be stored in a secure, environmentally controlled, and monitored 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 30 of 61 
Alexion Confidential  (manual or automated) area in accordance with the labeled storage conditions with access 
limited to the Investigator and authorized site staff.  
2. The Investigator and/or delegated staff (ie, Pharmacist) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).  
a. This responsibility includes the reporting of any product complaints to 
 within [ADDRESS_839238] or clinical study material and/or its packaging components after it is has been released for distribution to an end customer that affects the performa nce of such product. 
3. The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention. 
a. The ALXN1840 treatment kits should be stored at refrigerated conditions, 2°C to 8°C 
(36°F to 46°F). 
b. Ce
lecoxib should be stored according to the details in the package labeling. 
4. Further guidance and information for the final disposition of unused study interventions 
are provided in the Pharmacy Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
• This is an open- label,  2-period cross over study where, in order to minimize selection 
bias in treatment assignment, each participant will be randomized to  one of 
2 treatment sequences (Treatment  A and B). The randomization will be stratified by 
[CONTACT_629334].  
• Eligible participants who meet all inclusion and no exclusion criteria included in the 
study will be assigned unique study participant numbers for enrollment. Study 
participant numbers will not be reallocated once assigned.  
• To achieve balance between the number of males and females in the 2  sequences, the 
maximum split in either direction will be approximately 60%:40% (16 to 22 of each sex in each sequence).  
6.4. Study Intervention Compliance 
When participants are dosed at the site, participants will receive st udy intervention directly from 
the Investigator or designee, under medical supervision. The date and time of the dose will be 
recorded in the source documents and/or in the case report form (CRF). If the primary documentation is other than the electronic c ase report form (eCRF), all primary documentation 
should be filed on site as source documents. The dose of study intervention and study participant identification will be confirmed at the time of dosing by a member of the study site staff other 
[COMPANY_003]
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 31 of 61 
Alexion Confidential  than the person administering the study intervention. Study site personnel will examine each 
participant’s mouth to ensure that the study intervention was ingested. 
For additional information on study intervention compliance and management, refer to the 
Pharmacy Manu al. 
6.5. Concomitant Therapy  
Any medication or vaccine (including over - the -counter or prescription medicines, vitamins, 
and/or herbal supplements) or other specific categories of interest that the participant is receiving from [ADDRESS_839239] be recorded along 
with:  
• Reason for use. 
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency. 
The Medical Monitor should be contact[CONTACT_31182]. 
6.5.1. Allowed Medicine and Therapy  
• Paracetamol/acetaminophen at doses of a maximum 1,000  mg per day is permitted for 
use as an exception with the approval of the Investigator.  
• As per the ALXN1840 IB, in this study, Investigators should use caution in the 
co-administration of drugs known to be substrates of CYP2C9. Common substrates of 
CYP2C9 include ibuprofen, which is permitted in this study. Therefore, the 
Investigator must use ibuprofen with c aution during the conduct of the study. With 
the exception of the day of dosing in each period, ibuprofen may be used with the Investigator ’s approval; however, doses may not exceed 1,200 mg in any 24-hour 
period. 
• Topi[INVESTIGATOR_629319]’s discretion.  
• Concomitant medications are not allowed unless medically indicated and with 
agreement between Alexion and the Investigator . 
• Concomitant procedures are not allowed  unless medically indicated and/or permitted 
by [CONTACT_629335]. 
6.5.2. Disallowed Medicine and Therapy  
Participants must refrain from use or intended use of any prescription medications (excluding 
oral contraceptives) within 14  days or 5 half- lives o f the drug (whichever is longer) prior to 
dosing on Day 1 and for the duration of the study (ie, until completion of the EOS visit).  
Participants may not have a medical condition that requires chronic medicinal therapy. Use of 
nonprescription/over- the-counter medications, including COX-2 inhibitors, herbal remedies and 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 32 of 61 
Alexion Confidential  supplements, is not permitted within 7 days prior to dosing on Day 1 and for the duration of the 
study (ie, until completion of the EOS Visit).  
6.6. Dose Modification  
Not applicable. ALXN1840 and celecoxib will be administered as single doses in the prescribed parts of the study. 
6.7. Intervention After the End of the Study  
This is a healthy volunteer study and no follow-up intervention is planned. 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 33 of 61 
Alexion Confidential  7. DISCONTINUATION OF STUDY I NTERVENTION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention 
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) the study intervention. If the study intervention is definitively discontinued, the 
participant should remain in the study to be evaluated for safety follow-up. See the SoA  
(Table  1) for data to be collected at the time of discontinuation of study intervention and 
follow -up. 
Discontinuation of study intervention for abnormal liver function should be considered by [CONTACT_629336] (ie, AST or ALT) exceeds 3  × ULN or if the Investigator 
believes that it is in best interest of the participant.  
If a clinically significant finding is identified (including, but not limited to QTcF  ≥ 500 ms or 
QTcB ≥ 500 ms), the Investigator or qualified designee will determine if the participant can 
continue in the study and if any change in participant management is needed. Review of the ECG 
printed at the time of collection must be documented. Any new clinically relevant finding should 
be reported as an AE.  
Participant should be considered for discontinuation from intervention if any of the following 
occur during the study: 
• Serious hypersensitivity reaction;  
• Severe uncontrolled infection;  
• Use of disallowed medication  (Section  6.5.2); 
• Pregnancy or planned pregnancy (see Section  10.4); or 
• Alexion or the Investigator deems it is nec essary for the participant.  
See the SoA ( Table  1) for samples and data to be collected at the time of study intervention 
discontinuation and follow-up and for any further evaluations that need to be completed. 
7.2. Participant Discontinuation/Withdrawal From the Study  
• All efforts should be made to ensure participants are willing to comply with study 
participation prior to conducting the screening procedures. The study staff should notify Alexion and their site monitor of all study withdrawals as soon as possible. The 
reason for participant discontinuation must be recorded in the source documents and 
CRF.  
• A participant may withdraw from the study at any time at his/her own request or may 
be withdrawn at any time at the discretion of the Investigato r for safety, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. 
• At the time of discontinuing from the study, if possible, an Early Termination (ET) Visit should be conducted, as shown in the SoA ( Table  1). See the SoA for data to be 
collected at the time of study discontinuation and follow-up and for any further 
evaluations that need to be completed. 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 34 of 61 
Alexion Confidential  • The participant will be permanently discontinued both from the study intervention 
and from the study at that time.  
• If the participant withdraws consent for disclosure of future information, Alexion may retain and continue to use any data collected before such a withdrawal of consent. 
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the Investigator must document this in the site 
study records.  
7.3. Lost to Follow -up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_3433] e participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study. 
• Before a participant is deemed lost to follow -up, the Investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3  telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_14316]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.  
Discontinuation of specific site or of the study as a whole are handled as described in 
Section  10.1.8  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 35 of 61 
Alexion Confidential  8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summarized in the SoA ( Table  1). Protocol 
waivers or exemptions are not allowed. 
• Immediate safety concerns should be discussed with Alexion immediately upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The Invest igator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screen failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management 
(eg, blood count) and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol specified 
criteria and were performed within the time frame defin ed in the SoA. 
• Abnormal laboratory parameters may be repeated once during the Screening Period to 
ensure an accurate assessment of eligibility.  
• Unscheduled blood samples may be taken at the discretion of the Investigator for 
assessment of safety issues.  
8.1. Efficacy Assessm ents 
No efficacy assessments will be obtained during this study. 
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA ( Table  1). 
For study Periods 1 and 2, when multiple procedures are scheduled to occur at the same time, the following order of events should be strictly adhered to whenever possible: Vital signs, ECG, 
blood sampling, study intervention administration, and meal.  
Collection of samples for PK assessment should occur as close as possible to the scheduled time.  
8.2.1. Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal,  and neurological systems. It will be 
performed at Screening, C heck -in for each period, and at the EOS or upon ET. 
Height , BMI  (at Screening only) and weight will also be measured and recorded as 
outlined in the SOA ( Table  1). 
• A symptom-driven physical examination may be perfor med at other times, at the 
study physician’s discretion.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 36 of 61 
Alexion Confidential  • Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
8.2.2. Vital Signs  
• Oral temperature, pulse rate, respi[INVESTIGATOR_697], and systolic and diastolic blood pressu re 
(mm Hg) will be assessed.  
• Routine blood pressure and pulse measurements will be assessed with a completely 
automated device. Manual techniques should be used if repeat measurements are 
necessary due to abnormal results. 
• Blood pressure and pulse measurem ents should be preceded by [CONTACT_2669] [ADDRESS_839240] for the participant in a quiet setting without distractions (eg, television, cell phones). Ideally, the same arm for each participant should be used for measurements. 
8.2.3. Vital signs will be measured in a s emi-supi[INVESTIGATOR_55848] [ADDRESS_839241] . 
Electrocardiograms  
• Participants will be resting in the supi[INVESTIGATOR_21683] 15 minutes prior to and 
5 minutes after each nominal time point for ECG extraction. Triplicate 12 -lead ECG 
will be conducted as outlined in the SoA (see Table  1) to obtain heart rate, PR, QRS, 
QT, and QTc intervals. Heart rate and interval data will be recorded in the eCRF. QT 
corrected for heart rate using Fridericia’s formula should be recorded as the QTc 
reading (unless unavailable and then QTcB may be recorded) . Refer to Section  7 for 
QTc withdrawal criteria and any additional QTc readings that may be necessary.  
8.2.4. Clinical Safety Laboratory Assessments  
• See Section  10.[ADDRESS_839242] of clinical laboratory tests to be performed and the  SoA  
(Table  1) for the timing and frequency.  
• The Investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the AE section of the 
CRF. At the Investigator ’s discretion, all abnormal values may be repeated to confirm 
results. The laboratory reports must be filed with the source documents.  
• All laboratory tests with values considered clinically significantly abnormal during participation in the study after the last dose of the study intervention should be 
repeated until the values return to normal or baseline or are no longer considered 
clinically significant by [CONTACT_47998].  
− If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737], the etiology should be identified, and Alexion 
notified. 
− All protocol required laboratory assessments, as defined in Section 10.2, must be 
conducted in accordance with the laboratory manual and the SoA ( Table  1). 
− All laboratory values from nonprotocol specified laboratory assessments also 
must be recorded in the CRF.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 37 of 61 
Alexion Confidential  8.2.5. Suicidal Ideation and Behavior Risk Monitoring  
Not applicable. 
8.2.6. Pregnancy  
• Pregnancy data from female participants and female spouses/partners of male 
participants will be collected from the first dose of the study intervention through 
[ADDRESS_839243] immediately inform Alexion within 24 hours of awareness of the pregnancy and 
follow the procedures outlined in Section  10.4. 
• For all Alexion products, both in development or post approval , exposure during 
pregnancy must be recorded and the pregnancy followed until the outcome of the pregnancy is known (ie, spontaneous miscarriage, elective termination, normal birth, 
or congenital abnormality), even if the participant discontinues study intervention or 
withdraws from the study. The corresponding infant must be followed for 3 months 
postpartum. 
• Pregnancy is not considered an AE ( Section  10.4 ) unless there is a suspi[INVESTIGATOR_629320] a contraceptive medication. However, complications of pregnancy and abnormal outcomes of 
pregnancy are AEs and may meet the criteria for a SAE (eg, ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly) ( Section  8.3). Elective abortions without complications should not be 
reported as AEs.  
8.3. Adverse Events and Serious Adverse Events 
The definitions of AEs and SAEs can be found in Section  10.3. 
Adverse events will be repo rted to the Investigator or qualified designee by [CONTACT_2299] (or, 
when  appropriate, by a caregiver, surrogate, or the participant’s legally authorized 
representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study intervention  or study procedures, or that 
caused the participant to discontinue the study (see Section  7). 
Procedures for recording, evaluating, follow-up, and reporting AEs and SAEs are outlined in Section  10.3 . 
8.3.1. Time Period and Frequency for Collecting Adve rse Event and Serious Adverse 
Event Information  
All AEs will be collected from the signing of the ICF until the EOS or ET Visit.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 38 of 61 
Alexion Confidential  All SAEs will be recorded and reported to Alexion  or the designee immediately and under no 
circumstance should this exceed  24 hours, as indicated in Section  10.3. The Investigator will 
submit any updated SAE data to Alexion within 24 hours of it being available. 
Investigators are not obligated to actively seek AEs or SAEs after conclusion of the study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after 
a participant has exited the study, and he/she considers the event to be reaso nably related to the 
study intervention , the Investigator must promptly notify Alexion. 
8.3.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in Section  10.3 .  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow -up with each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -up (as defined in 
Section  7.3). Further information on follow -up procedures is provided in Section  10.3 .  
8.3.4. Regulatory Reporting Requirements for SAEs 
• Prompt notification by [CONTACT_629337] a study intervention  under clinical investigation are met.  
• Alexion has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. Alexion will comply with country- specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs), and Investigators. 
• Suspected unexpected  serious adverse reactions (S[LOCATION_003]Rs) must be reported 
according to local regulatory requirements and Alexion policy and forwarded to Investigators as necessary.  
• An Investigator who receives an Investigator Safety Report describing an SAE or 
other specific safety information (eg, summary or listing of SAEs) from Alexion will review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  
8.3.5. Adverse Events of Special Interest  
There are no adverse events of sp ecial interest for this study.  
Original Protocol [ADDRESS_839244] medical 
occurrence resulting from the overdose. 
In the event of an overdose or suspected overdose, the Investigator or treating physician should: 
• Contact [CONTACT_27465].  
• Closely monitor the participant for any AE/SAE.  
• Obtain a plasma sample for PK analysis if requested by [CONTACT_1689] (determined 
on a case -by-case basis) .  
• Document the quantity of the excess dose as well as the duration of the overdose in the CRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_288953]. 
8.5. Pharmacokinetics  
• Whole blood samples will be collected for the measurement of plasma concentrations of total Mo and celecoxib as specified in the SoA ( Table  1). Additional samples may 
be collected at additional time points during the study if warranted and agreed upon 
between the Investigator and Alexion. Collection of samples for PK evaluation should 
occur as close as possible to the scheduled time and actual time of collection should be documented on the eCRF. Samples collected within ± 10% of the scheduled time, 
or 30 minutes whichever is larger, will not be considered a protocol deviation. In the 
event of a safety occurrence and after agreement between the Investigator and Medical Monitor, up to 3 additional PK  sampling timepoints may be added.  
• Instructions for the collection and handling of biological samples will be provided by [CONTACT_57747]. The actual date and time (24- hour clock time) of each sample will be 
recorded.  
• Samples will be used to evaluate the effect of ALXN1840 on the PK of celecoxib. Samples collected for analyses of plasma concentrations may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 40 of 61 
Alexion Confidential  • Excess/additional samples may be stored for up to 5 years and used for 
pharmacodynamic (PD) development and research to understand the pathways 
associated wit h the mechanism of action of ALXN1840; however, samples will not 
be used for genetic analyses (ie RNA or DNA analyses).  
8.6. Pharmacodynamics 
Plasma samples collected for PK may be used for analyzing the PD of ALXN1840 including, but not limited to plasma total Cu, ceruloplasmin (Cp), Cp-bound Cu (CpC), and potentially toxic Cu measured as labile -bound Cu (LBC) and PUF Cu and/or assessed via NCC/NCC
corrected . 
8.7. Genetics  
Blood samples for genetic testing of CYP2C9 polymorphism will be collected at clinical Check -in (Day  -1). This study proposes to collect genetic polymorphism data to characterize 
potential impact of ALXN1840 on phenotypic CYP2C9 metabolism of celecoxib and evaluate the potential effect of genetic polymorphism on the between -participant variability of celecoxib 
PK. As this is an exploratory assessment, the study will not specifically select target participants 
with a certain proportion of CYP2C9 genotypes.  
8.8. Biomarkers  
Biomarkers are not evaluated in this study.  
8.9. Immunogenicity 
Not applicable. 
8.10. Health Economics and Medical Resource Utilization  
Health economic and medical resource utilization parameters are not evaluated in this study. 
Original Protocol [ADDRESS_839245] of ALXN1840 on 
the metabolism of celecoxib, the sample size was determined using the conservative 90% 
confidence interval (CI) and 80% to 125% no-effect boundary approach described  in the FDA 
Guida nce “Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and 
Transporter- Mediated Drug Interactions” (2020). This guidance notes the 80 to 125 % 
boundaries represent a very conservative standard for drugs that have wide safety “margins” and 
“the to tality of evidence should be taken into consideration when determining the clinical impact 
of the DDI on the substrate drug”. Therefore, if the estimated inhibition effect of ALXN1840 on 
celecoxib PK lies outside this no -effect boundary, this should not be interpreted as a failed study.  
9.2. Sample Size Determination  
A default of no -effect boundary (80% to 125%) approach will be employed to assess whether 
there is an inhibition effect on the metabolism of celecoxib in the presence of ALXN1840. For a 
2-period crossover study design, assuming the true ratio of the means (celecoxib + ALXN1840 
vs celecoxib alone) on the PK parameters is 1 (C max; area under the plasma concentration versus 
time curve from zero to infinity [AUC ∞]) and the intra -participant coefficient of variation (CV) is 
0.30 ( Dennison, 2018) , a total sample size of 32 participants can achieve 90% power with two 
1-sided test s, each with a type I error rate of 5% (two -sided type I error rate of 10%). The intra-
participant CV is estimated using residual mean -square error (MSE) term in the ANOVA model. 
The CV is estimated as 100%  × √ (exp  (MSE) - 1) for the log -transformed PK parameters.  
Assuming a 15% dropout rate, approximately 38 participants will be enrolled.  
9.3. Populations for Analyses  
The following populations are defined  (Table  6): 
Table  6: Populations for Analyses 
Population  Description  
Enrolled Set All participants who sign the ICF  
Safety Set  All participants who receive at least 1 dose of study intervention  
Pharmacokinetic/Pharmacodynamic  
(PK/PD)  Analysis Set  All participants who have sufficient  plasma samples to have evaluable PK 
data for celecoxib and total Mo (as a measure of ALXN1840) in plasma  
Abbreviation: ICF  = informed consent form; Mo = molybdenum . 
9.4. Statistical Analyses  
Statistical methods described in this section will be further elabo rated in a separate Statistical 
Analysis Plan (SAP). The SAP will be developed and approved before database lock and will 
describe the participant  populations to be included in the analyses, and procedures for accounting 
for missing data.  
Original Protocol [ADDRESS_839246] deviation, median, minimum, and maximum. Categorical 
variables will be summarized using percentages and frequency counts.  
All statistical analyses will be conducted using SAS® for Windows® Version 9.3 or higher. 
9.4.1. Efficacy Analyses 
No efficacy analyses will be performed for this study. 
9.4.2. Safety Analyses 
All safety analyses will be performed on the Safety Set.  
Safety analyses will include an analysis of all AEs, ECGs, clinical laboratory data, physical 
examinations, and vital sign measurements using descriptive statistics. Data will be summarized 
by [CONTACT_629338].  
No inferential statistical analyses are planned for the safety parameters of this study. The 
incidence of AEs and SAEs will be summarized by [CONTACT_1196] (SOC) and Preferred 
Term for each treatment and overall, and by [CONTACT_284519] . Adverse events 
will also be summarized by [CONTACT_288956]. Serious AEs and AEs resulting in 
withdrawal from the study will be listed. Participants having multiple AEs within a category 
(eg, overall, SOC, Preferred Term) will be counted once in that category. For severity tables, a participant’s most severe event within a category will be counted.  
Changes from baseline in vital sign measurements and laboratory assessments (eg, chemistry, blood cell count with differential, and urinalysis) will be summarized by [CONTACT_629338]. Laboratory parameter values will be graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE). Shift tables by [CONTACT_629339]. These tables will summarize the number of participants with each baseline grade relative to the reference ranges and changes to the worst highest grade 
assessed post -dose during the study.  
Electrocardiogram  parameters will be measured at the specified time points, including heart rate, 
PR, RR, QRS, QT, and corrected QTcF intervals. The average of the triplicate ECG readings at the time points collected will be calculated, and changes from pretreatment baseli ne values will 
be assessed by [CONTACT_91014].  
All concomitant medications will be coded and summarized using the World Health Organization (WHO) Drug Dictionary.  
9.4.3. Other Analyses  
[IP_ADDRESS]. Pharmacokinetic and Pharmacodynamic Analyses  
Pharmacokinetic analyses will be performed using the P K/PD Analysis Set.  
Blood samples for PK analysis of total Mo (as a measure of ALXN1840) and celecoxib will be 
collected at the following time points: pre -dose and post -dose at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 
96, 120, 144, 168, 192, 216, 240, and 336 hours in each period.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 43 of 61 
Alexion Confidential  The following plasma PK parameters will be calculated as endpoints for total Mo and celecoxib 
using noncompartmental methods with Phoenix® WinNonlin® (Certara [LOCATION_003] Inc., Princeton, 
New Jersey) Version 8.0 or higher or SAS Version 9.3 or higher (SAS Institute Inc., Cary, North 
Carolina), as applicable. Calculations will be based on the actual sampling times recorded during the study. 
• Time delay between the time of dosing and time of appearance of drug concentration in plasma (T
lag; for plasma total Mo with ALXN1840 administration)  
• Maximum observed concentration in plasma (C max) 
• Time to C max (Tmax)   
• Area under the plasma concentration (AUC) versus time curve from time [ADDRESS_839247] quantifiable concentration (AUC
t) 
• AUC versus time curve from time 0  to infinity (AUC ∞)  
• AUC extrapolated from time t to infinity as a percentage of AUC ∞ (%AUCextrap)  
• Apparent terminal-phase elimination rate constant (λ z) 
• Terminal elimination half- life (t ½) 
• Apparent or al clearance (CL/F)  
• Apparent volume of distribution (V d/F) 
Additional plasma PK parameters may be calculated if deemed appropriate.  
Plasma concentrations of total Mo and celecoxib and time deviation data will be presented in a data listing by [CONTACT_3445]. Plasma concentration data will be summarized separately by [CONTACT_629340]: number of 
participants, arithmetic mean, SD, coefficient of variation (CV), median, minimum, and maximum. Mean plasma concentration versus scheduled time profiles will be presented in 
figures on both linear and semilogarithmic scales. Individual plasma concentration versus actual 
time profiles will be presented similarly.  
Pharmacokinetic parameters derived from pla sma concentrations of total Mo and celecoxib will 
be presented in data listings and summarized separately using the following descriptive statistics: number of participants, arithmetic mean, SD, arithmetic CV, median, minimum, maximum, and 95% CI. Geometri c mean and geometric CV will be presented for C
max and AUCs only. 
The effect of ALXN1840 on celecoxib PK will be assessed using a linear mixed‐effect model 
(SAS PROC MIXED) with treatment condition, sequence, and period as fixed effects and participant nested within sequence as a random effect . The model will be fitted to the natural‐
log‐transformed PK parameters C
max, AUC ∞ and AUC t for estimation of effects and construction 
of CI s for the test treatment (Treatment B: 200  mg celecoxib  + 60 mg ALXN1840) compared 
with the reference treatment (Treatment A: 200  mg celecoxib). The within- participant CV for the 
corresponding PK parameters will be estimated using the mean squared error fro m the statistical 
model . Confidence intervals (90%) will be constructed for the least- squares geometric mean ratio 
(GMR) estimates between the test and reference treatments for above PK parameters using the 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 44 of 61 
Alexion Confidential  natural log -transformed data. The GMR estimates and the associated 90% confidence limits will 
be exponentiated back to the original scale.  
Analyses of other PK data including, but not limited to PUF Mo may be conducted. 
Pharmacodynamic data of ALXN1840 including, but not limited to, plasma total Cu, Cp, CpC, 
and potentially toxic Cu measured as LBC and PUF Cu and/or assessed via NCC/NCC corrected  
may be analyzed and reported. 
Details of the PK/PD analyses will be described  in the PK/PD data analysis plan or included in 
the SAP, which will be finalized before database lock.  
9.5. Interim Analyses  
No interim analyses are planned for this study. 
9.6. Data Monitoring Committee 
There will not be a Data Monitoring Committee , but provision is included for an ad hoc Safety 
Review Committee (SRC), if needed.  
9.7. Safety Review Committee 
To ensure participant safety, ad hoc SRC meetings may be held to discuss urgent issues should 
the need arise. The ad hoc SRC must convene within 24 hours in the cas e of a TESAE  or the 
withdrawal of any participant due to an adverse reaction. 
The ad hoc SRC, consisting of the Investigator, Alexion Safety Physician and Alexion Medical 
Monitor will evaluate the study data, if needed, for participant safety and make recommendations 
on termination of the study.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 45 of 61 
Alexion Confidential  10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for Internati onal Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
− Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines  
− Applicable laws and regulations 
• The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_6661]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval and, where applicable, competent authority approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to 
study participants.  
• The Investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC . 
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC proc edures. 
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all 
other applica ble local regulations . 
10.1.2. Financial Disclosure  
Investigators and Sub- Investigators will provide Alexion with sufficient, accurate financial 
information as requested to allow Alexion to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after 
completion of the study. 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 46 of 61 
Alexion Confidential  10.1.3. Informed Consent Process  
• It is the responsibility of the Investigator to obtain signed (written or electronic 
signature) informed consent from all study participants prior to any study -related 
procedures including screening assessments.  
• The Investigator or his/her representative will explain the nature of th e study 
(including but not limited to the objectives, potential benefits and risk, 
inconveniences, and the participant’s rights and responsibilities) to the participant, 
defined according to local and country regulations where the study is taking place, and answer all questions regarding the study.  
• Participant s must be informed that their participation is voluntary. Participants, or 
their legally authorized representative, will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
European Union (EU) General Data Protection Regulation (GDPR), ICH guidelines, 
Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained before the participant  was screened in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF(s).  
• Participant s must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the signed (written or electronic) documentation (ie, a complete set of 
participant information sheets and fully executed signature [CONTACT_1787]) must be provided to the participant or the participant’s  legally authorized representative, as applicable. 
This document may require translation into the local language. Signed (written or electronic) consent forms must remain in each participant’s study file and must be available for verification at any time.  
• The ICF will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The I nvestigator or authorized designee 
will explain to each participant the objectives of the exploratory research. If sharing 
exploratory research results with the Investigator is not planned, the ICF should mention it. Participants or legally authorized representative will be told that they are free to refuse to participate and may withdraw their consent at any time and for any 
reason during the storage period. A separate signature [CONTACT_22862] a participant’s agreement to allow any remaining specimens to be used for exploratory research. Participants who decline to participate in this optional research will not 
provide this separate signature . 
10.1.4. Data Protection 
• Participants will be assigned a unique identifier by [CONTACT_57747]. Any participant records 
or datasets that are transferred to Alexion will contain the identifier only; participant 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 47 of 61 
Alexion Confidential  names or any information  which would make the participant identifiable will not be 
transferred.  
• The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_288960]. The level of disclosure must 
also be ex plained to the participant who will be required to give consent for their data 
to be used as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined by [CONTACT_629341] a uthorized personnel appointed by 
[CONTACT_57747], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
10.1.5. Dissemination of Clinical Study Data  
Study-related information and study results may be posted on publicly accessible clinical study 
databases (eg, the US website www.clinicaltrials.gov  or the EU website 
www.clinicaltrialregister.eu ), as appropriate, and in accordance with national, regional, and local 
regulations. 
10.1.6. Data Quality Assurance 
• All participant  data relating to the study will be recorded on a printed or electronic 
CRF unless transmitted to Alexion or designee electronically (eg, laboratory data). 
The Investigator is responsible for verifying that data entries are accurate and correct 
by [CONTACT_1189].  
• The Investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct ac cess to source data documents.  
• Alexion or its designee is responsible for the data management of this study including 
quality checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently approved protocol and any other s tudy agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_13177] [ADDRESS_839248] article for investigation, unless local regulations or institutional policies require a 
longer retention period. No records may be destroyed during the retention period without the written a pproval of Alexion. No records may be transferred to another 
location or party without written notification to Alexion.  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 48 of 61 
Alexion Confidential  10.1.7. Source Documents  
Source documents provide evidence for the existence of the participant  and substantiate the 
integrity of the data collected. The Investigator or designee will prepare and maintain adequate 
and accurate source documents (eg, medical records, ECGs, AE and concomitant medication 
reporting, raw data collection forms) designed to record all observations and other pertinent data for each participant.  
Data reported in the CRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical 
records must be available. Source documents are filed at the Investigator’s site.  
10.1.8. Study and Site Start and Closure  
The study start date is the date on which the first participant signs the informed cons ent.  
Alexion or its designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of Alexion. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have been collected and a study site closure visit has been performed.  
The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_629342]: 
• Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, Alexion ‘s procedures, or GCP guidelines 
• Inadequate recruitment of participants by [CONTACT_737]  
• Discontinuation of further study intervention development 
If the study is prematurely terminated or suspended, Alexion shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator shall promptly infor m the participant and 
should assure appropriate therapy and/or follow-up. 
10.1.9. Publication Policy  
• Where possible, primary manuscripts reporting results of the primary efficacy 
endpoint or the final results will be submitted for publication within 12  – 18 months 
of the primary evaluation date or end of study, whichever is earlier.  
• Investigators who participate as authors in manuscripts derived from Alexion- sponsored studies will agree to the prerequisites as outlined in the Alexion 
author engagement agreement prior to engaging in manuscript development.  
• The Investigator agrees to submit proposals for new manuscripts (whether or not the 
proposed analyses are derived from protocol-specified endpoints) to Alexion for 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 49 of 61 
Alexion Confidential  review and consideration. All manuscripts or abs tracts emanating from approved 
proposals are to be submitted to Alexion for review before submission to the 
journal/society. This allows Alexion to protect proprietary information and to provide 
comments.  
− The proprietary nature of some development work may preclude publication. In 
some cases, it may be necessary to delay a publication to allow Alexion to ensure 
protection of intellectual property.  
• In general, primary publications, including congress and journal publications, 
containing the protocol- specif ied results of a study should occur prior to the 
publication of individual study site results or case reports. Alexion’s policy prohibits 
duplicate publication, whereby [CONTACT_468855]-reviewed journal manuscripts.  
− Encore congress publications may be appropriate to allow communication of 
research findings to relevant audience and geographical regions. 
• Alexion will comply with the requirements for publication of study results. In accordance with standard editorial and  ethical practice, Alexion will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating I nvestigator will be designated by [CONTACT_231692].  
• Authorship will be determined by [CONTACT_629343].  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 50 of 61 
Alexion Confidential  10.2. Appendix 2: Clinical Laboratory Tests 
• The tests detailed in Table  7 will be performed by [CONTACT_12082].  
• Protocol- specific requirements for inclusion or exclusion of participants are detailed 
in Section  5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_9332]. Investigators must 
document their review of each laboratory safety report and indicate whether out of range results are clinically significant (“CS”) or not clinically significant (“NCS”).  
• Women of childbearing potential should only be enrolled after a negative serum pregnancy te st result at screening. Additional urine pregnancy testing will be standard 
for the protocol unless serum testing is required by [CONTACT_288926], local regulation, or 
IRB/IEC and should be performed per the time points specified in the 
SoA(Table  1).Screening pregnancy criteria are detailed in Section  5.1. 
Table  7: Protocol- Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count  
Red blood cell count  
Hemoglobin  
Hematocrit  RBC Indices : 
Mean corpuscular volume  
Mean corpuscular hemoglobin  
% Reticulocytes  WBC  count with 
differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Clinical Chemistry  BUN  
Potassium  
Bicarbonate  
Sodium  
Glucose  
AST  
ALT 
Chloride  Alkaline phosphatase  
Direct bilirubin  
Total bilirubin  
Albumin  
Creatinine  
Creatine phosphokinase  
Coagulation  INR  
Partial thromboplastin time  
Prothrombin time  
Routine Urinalysis  Specific gravity  
pH 
Glucose  
Protein  
Blood 
Bilirubin  
Urobilinogen  
Nitrite  
Leukocyte esterase by [CONTACT_629344] a lcohol and urine drug screen (to include at minimum: amphetamines, 
barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, opi[INVESTIGATOR_858], phencyclidine, methamphetamine, 3,4methylenedioxy- methamphetamine, methadone, and tetr ahydrocannabinol 
[cannabinoids])
  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 51 of 61 
Alexion Confidential  Table  7: Protocol- Required Safety Laboratory Assessments (Continued)  
Laboratory 
Assessments  Parameters  
 Human immune deficiency virus (HIV) -1 and HIV -2 antibodies, HbsAg, anti -HBC IgG + 
IgM (if IgG positive), and anti - HCV with confirmation by [CONTACT_629345] (as needed for women of childbearing potential)  
 FSH (postmenopausal females only)  
Note: All events of ALT ≥  3 × upper limit of normal (ULN) and bilirubin ≥ 2 × ULN (>  35% direct bilirubin) or 
ALT ≥ 3 × ULN and international normalized r atio (INR) >  1.5, if INR measured which may indicate severe liver 
injury (possible Hy’s Law), must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis).  
 
Abbreviations: ALT  = alanine aminotransferase; AST  = aspartate aminotransferase; BUN  = blood urea nitrogen; 
FSH = follicle -stimulating hormone; HbsAg  = hepatitis B surface antigen; HbA1C  = hemoglobin A1C;  
HBC = hepatitis B core antigen ; hCG  = human chorionic gonadotropin; HCV  = hepatitis C virus; HIV  = human 
immunodeficiency virus; Ig = immunoglobulin; INR = international normalized ratio;  RBC  = red blood cell ; 
RNA  = ribonucleic acid ; WBC  = white blood cell . 
Investigators must document their review of each laboratory safety report.  
 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 52 of 61 
Alexion Confidential  10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting 
10.3.1. Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a participant, temporally asso ciated with the use of study 
intervention, whether or not considered related to the study intervention.  
• Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) te mporally associated with the use of study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety 
assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the medical and scientific judgment of the Investigator.  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in frequency 
and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug intera ction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self -harm ing intent. Such overdoses should be reported regardless of 
sequelae.  
 
Events Not Meeting the AE Definition  
• Medical or surgical procedure (eg, endoscopy, appendectomy): The condition that leads to the procedure is 
the AE. Situations in which an untoward medical occurrence did not occur (eg, hospi[INVESTIGATOR_288911], admissions for social reasons or for convenience).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) pr esent or detected at the start of 
the study that do not worsen.  
• A medication error (including intentional misuse, abuse, and overdose of the product) or use other than what is defined in the protocol is not considered an AE unless there is an untoward medical occurrence as a result of a medication error.  
• Cases of pregnancy that occur during maternal or paternal exposure to study intervention are to be reported within 24 hours of Investigator/site awareness. Data on fetal outcome and breastfeeding will be collected for 
regulatory reporting and safety evaluation.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a 
hospi[INVESTIGATOR_307]).  
10.3.2. Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
1. Results in death  
2. Is life-threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the participant was at risk of 
death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it 
was more severe.  
Original Protocol [ADDRESS_839249] medical occurrence that, at any dose:  
3. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an overnight 
stay) at the hospi[INVESTIGATOR_625943] o bservation and/or treatment that would not have been appropriate in 
the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], th e event is serious. When in doubt as 
to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is not 
considered an AE.  
4. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) 
which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.  
5. Is a congenital anom aly/birth defect  
6. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in 
other situations such as important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_629321]. These events should usually be considered serious. 
• Examples of such events include invas ive or malignant cancers, intensive treatment in an emergency room 
or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], 
or development of drug dependency or drug abuse.  
10.3.3. Recording and Follow -Up of AE and/or SAE  
Recording of AE and/or SAE  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (eg, hospi[INVESTIGATOR_41100], laboratory reports, and diagnostics reports) related to the event.  
• The Investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical records to Alexion in lieu of completion of the AE/SAE CRF page.  
• There may be instances whe n copi[INVESTIGATOR_288913]. In this 
case, all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_298115].  
• The Investi gator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be 
documented as the AE/SAE.  
Assessment of Intensity  
 
The Investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to one of the following categories from National Cancer Institute CTCAE v5.0, published 27 Nov 2017:  
• Grade 1: Mild (awareness of sign or symptom, but easily tolerated)  
• Grade 2: Moderate (discomfort sufficient to cause interference with normal activities)  
• Grade 3: Severe (incapacitating, with inability to perform normal activities)  
• Grade 4: Life -threatening  
• Grade 5: Fatal  
 
Assessment of Causali ty 
• The Investigator is obligated to assess the relationship between the study intervention and each occurrence 
of each AE or SAE. An Investigator causality assessment must be provided for all AEs (both nonserious and 
serious). This assessment must be recorded in the CRF and on any additional forms, as appropriate. The 
definitions for the causality assessments are as follows:  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 54 of 61 
Alexion Confidential  Assessment of Causali ty 
− Not related: There is no reasonable possibility the study intervention caused the AE.  
 The AE has a more likely alternative etiology; it may be due to underlying or concurrent 
illness, complications, concurrent treatments, or effects of another concurrent drug.  
 The event does not follow a reasonable temporal relationship to administration of the study 
intervention.  
− Related: There i s a reasonable possibility the study intervention caused the AE.  
 The AE has a temporal relationship to the administration of the study intervention.  
 The event does not have a likely alternative etiology.  
 The event corresponds with the known pharmaceutical  profile of the study intervention.  
 There is improvement on discontinuation and/or reappearance on rechallenge.  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the 
temporal relationship of the event to study intervention administration will be considered and investigated.  
• The Investigator will also consult the Investigator’s Brochure (IB)  in his/her assessme nt. 
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred, and the Investigator has minimal information to 
include in the initial report to Alexion. However, it is very important that the Investigator always make an 
assessment of causality for every event before the initial transmission of the SAE data to Alexion.  
• The Investigator may change his/her opi[INVESTIGATOR_9242] -up information and send an SAE 
follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
 
Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluations as medically indicated or as requested by [CONTACT_288963]/or causality of the 
AE or SAE as fully as possible. This may inclu de additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up period, the 
Investigator will p rovide Alexion with a copy of any post -mortem findings including histopathology.  
• New or updated information will be recorded in the originally completed CRF.  
• The Investigator will submit any updated SAE data to Alexion within 24 hours of receipt of the 
information.  
10.3.4. Reporting of SAEs  
SAE Reporting to Alexion GDS via Paper Safety Reporting Form  
• All SAEs will be recorded and reported to Alexion or designee immediately and within 24 hours 
awareness.  
• SAEs will be reported using the Safety Reporting Form and submitted to Alexion Global Drug Safety 
(GDS). The Investigator must complete, sign, and date the SAE pages, verify the accuracy of the 
information recorded on the SAE pages with the corresponding source documents, and send a copy via 
email or facsimil e to the contact [CONTACT_51259]:  
− Email:  or Fax:  
• Additional follow -up information, if required or available, should be entered into the CRF and sent to 
Alexion GDS within 24 hours of the Investigator or s tudy site staff becoming aware of this additional 
information via the reporting process outlined above.  
• For all SAEs, the Investigator must provide the following:  
− Appropriate and requested follow -up information in the time frame detailed above  
− Causality o f the SAE(s)  
− Treatment of/intervention for the SAE(s)  
− Outcome of the SAE(s)  
− Medical records and laboratory/diagnostic information  
[COMPANY_003]
[COMPANY_003]
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 55 of 61 
Alexion Confidential  SAE Reporting to Alexion GDS via Paper Safety Reporting Form  
• All paper forms and follow -up information submitted to Alexion GDS must  be accompanied by a cover 
page signed by [CONTACT_18613].  
• Paper source documents and/or reports should be kept in the appropriate section of the study file.  
 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 56 of 61 
Alexion Confidential  10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
 
• CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
• Highly Effective Methodsb That Have Low User Dependency  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD): female participants with a Cu -containing I UD  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Vasectomized partner  
o (Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. Spermatogenesis cycle is 
approximately 90 days.)  
• Highly Effective Methodsb That Are User Dependent  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
o Oral 
o Injectable  
• Sexual abstinence  
o (Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.)  
• Female participants of non-childbearing potential are exempt from contraception requirements. Non-
childbearing potential for female patients is defined as any of the following:  
o Prior to first menses  
o Postmenopausal, as documented by [CONTACT_213665] 1 year prior to the Day 1 visit and follicle 
stimulating hormone (FSH) serum levels consistent with postmenopausal status  
o Permanent sterilization at least 6 weeks prior to the Day 1 visit:  
− Hysteroscopic sterilization  
− Bilateral tubal ligation or bilateral salpi[INVESTIGATOR_1656]  
− Hysterecto my 
− Bilateral oophorectomy  
a) Contraceptive use by [CONTACT_103092].  
b) Failure rate of < 1% per year when used consistently and correctly. Typi[INVESTIGATOR_17964].  
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit  ovulation as the primary mode of action.  
 
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for 
this study. Male condom and female condom should not be used together (due to risk of fai lure with friction)  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 57 of 61 
Alexion Confidential  • Collection of pregnancy information  
o If a female participant or a male participant’s female spouse/partner becomes pregnant during the 
conduct of this study, the Investigator must submit the “Pregnancy/Breastfeeding Reporting and 
Outcom e Form" to Alexion Global Drug Safety (GDS) via fax or email (see Section  10.3 [Appendix 3] 
for contact [CONTACT_3031]). When the outcome of the pregnancy becomes known, the form should be updated and submitted to Alexion GDS. If additional follow up is required, the Invest igator will be 
requested to provide the information.  
o Exposure of an infant to an Alexion product during breastfeeding must also be reported (via the “Pregnancy/Breastfeeding Reporting and Outcome Form”) and any AEs experienced by [CONTACT_629346] d to Alexion GDS or designee via email or facsimile (see Section  10.[ADDRESS_839250] 
information).  
 
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 58 of 61 
Alexion Confidential  10.5. Appendix 5: Abbreviations  
A list of abbreviations an d terms are used in this study protocol is provided in Table  8. 
Table  8: List of Abbreviations and Definitions of Terms  
Abbreviation  Definition  
λz apparent terminal -phase elimination rate constant   
AE adverse event   
ALT alanine aminotr ansferase  
ANOVA  Analysis of Variance   
AST  aspartate aminotransferase   
AUC  area under the plasma concentration versus time curve  
AUC t area under the plasma concentration versus time curve from time [ADDRESS_839251] 
quantifiable concentration   
AUC ∞ area under the plasma concentration versus time curve from zero to infinity   
BMI  body mass index  
BUN  blood urea nitrogen  
CYP  cytochrome P450   
CYP2C9  cytochrome P450 2C9  
CFR  Code of Federal Regulations  
CI confidence interval  
CIOMS  Council for International Organizations of Medical Sciences  
CL/F  apparent oral clearance   
Cmax maximum observed  plasma concentration   
CONSORT  Consolidated Standards of Reporting Trials   
Cp ceruloplasmin  
CpC ceruloplasmi n-bound  copper  
CRF  case report form  
CRU  clinical research unit   
CTCAE  Common T erminology  Criteria for Adv erse Events  
CTFG  Clinical Trial Facilitation Group  
Cu copp er  
CV arithmetic coefficient of variation  
DDI Drug -Drug Interactions  
EC enteric -coated   
ECG  electrocardiogram  
eCRF  electronic  case report form 
EMA  European Medicines Agency  
EOS End of  Study  
ET Early Termin ation 
EU European Union  
FDA  Food and Drug Administration  
Original Protocol [ADDRESS_839252]   
HIV human immunodeficiency virus  
HLM  human liver microsomes  
IB Investigator’s Brochure   
IC50 value  drug concentration required to produce 50% of the maximal inhibition  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee   
INR international normalized ratio  
IRB Institutional Review Board  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
LAM  lactational amenorrhoea method  
LBC  labile -bound copper  
Mo molybdenum   
MSE  mean-square error  
MTD  maximum tolerated dose  
NCC  non-ceruloplasmin -bound copper   
NCC corrected  corrected NCC  
NCS  not clinically significant  
PBC  primary biliary cholangitis  
PD Pharmacodynamic (s) 
PI [INVESTIGATOR_244278](s)   
PMDA  Pharmaceuticals and Medical Devices Agency  
PUF plasma ultrafiltrate   
QT interval between the start of the Q wave and the end of the T wave in an ECG   
QTcB  QT interval corrected for heart rate using Bazett’s formula  
QTcF  QT interval corrected for heart rate using Fridericia’s formula   
RBC  red blood cell  
RNA  ribonucleic acid  
SAE  serious adverse  event   
SAP Statistical Analysis Plan   
SoA Schedule of Activities  
SOC  System Organ Class  
Original Protocol [ADDRESS_839253]  upper limit of normal  
USPI  [INVESTIGATOR_629322]/F apparent volume of distribution   
WD Wilson Disease   
WHO  World Health Organization  
Original Protocol 28 Apr 2020  ALXN1840 -HV-105 
Page 61 of 61 
Alexion Confidential  11. REFERENCES  
Celebrex®. CELEBREX ® (celecoxib) capsules (USPI).[COMPANY_007]; Revised May, 2019.  
Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and 
Clinical Considerations. J Pers Med. 2017;8(1). 
Dean L. Celecoxib Therapy and CYP2C9 Genotype. In: Pratt VM, McLeod HL, Rubinstein WS, 
Scott SA, Dean LC, Kattman BL, et al., editors. Medical Genetics Summaries. Bethesda 
(MD)2012. 
Dennison J, Puri A, Warrington S, Endo T, Adeloye T, Johnston A. Amenamevir: Studies of 
Potential CYP2C8- and CYP2B6 -Mediated Pharmacokinetic Interactions With Montelukast and 
Bupropi[INVESTIGATOR_629323]. Clin Pharmacol Drug Dev. 2018;7(8):860-870. 
Diflucan®. DIFLUCAN ® (fluconozole) tablet (USPI). [COMPANY_007]; Revised Feb, 2019. . 
US Food and Drug Administration. Drug Development and Drug Interactions: Table of 
Substrates, Inhibitors and Inducers, Revised Dec 2019. 
Weiss K, Askari F, Czlonkowska A, et al. Bis- choline tetrathiomolybdate in patients with 
Wilson's disease: an open -label, multicentre, phase [ADDRESS_839254] roenterol Hepatol. 
2017;12:869-876.  